Peptide 6C increases cerebral blood flow. Adapted from Meena et al. Royal Society of Chemistry Advances (2015) 5:56872-56884

Peptide 6c can easily cross the blood brain barrier and is relatively stable metabolically [13]. In fact, peptide 6c is much more stable than its parent molecule because it does not contain any sites for proteases in blood or the gastrointestinal tract (ie. enzymes that break down proteins). Moreover, when given peripherally or intranasally, this peptide 6c is effective and free of adverse effects that are seen in the full-length CNTF protein. Multiple studies have observed the absence of any unwanted weight fluctuations or abnormal locomotor activity in peptide 6c treated individuals. Importantly, peptide 6c has been shown to reliably increase cerebral blood flow, which is a crucial metric for assessing neurotrophic activity in general.